Literature DB >> 32337825

High-immunological risk living donor renal transplant during the COVID-19 outbreak: Uncertainties and ethical dilemmas.

Quan Yao Ho1,2, Shimin J Chung3,2, Valerie H L Gan4,2, Lay Guat Ng4,2, Ban Hock Tan3,2, Terence Y S Kee1,2.   

Abstract

Entities:  

Keywords:  clinical decision-making; clinical research/practice; ethics; ethics and public policy; infection and infectious agents - viral; infectious disease; kidney transplantation/nephrology

Mesh:

Year:  2020        PMID: 32337825      PMCID: PMC7267290          DOI: 10.1111/ajt.15949

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


× No keyword cloud information.
To the Editor: We describe the challenges of performing a high‐immunological risk living donor renal transplant during the coronavirus disease 2019 (COVID‐19) outbreak. A 42‐year‐old woman with end‐stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuroperitoneal leak, failed vascular access creation due to early thrombosis, and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO incompatible and had positive B cell flow crossmatch with multiple donor‐specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable. Ethics approval for transplant was obtained in February 2020 just as limited local transmission was reported. The pair decided to proceed after extensive discussions with a multidisciplinary team. Hospital‐wide infection control was enhanced since January 2020. COVID‐19 cases and suspects are segregated and allocated dedicated radiology and operating resources. , Healthcare workers are required to report temperature twice daily, cease travel to affected countries, and don surgical masks in all clinical settings. In addition, COVID‐19 cases or suspects are cared for by separate dedicated teams. The pair and their appointed caregivers were counseled on strict adherence to personal hygiene, social distancing measures, and travel restrictions. The recipient was nursed in a single room and allowed only one visitor. The pair required negative nasopharyngeal swabs for the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus and normal chest radiographs at 14 and 2 days before surgery. On March 11, 2020, as desensitization was ongoing and just 1 week before surgery, the World Health Organization declared a global pandemic. Our immunoadsorption column supply was threatened due to export restrictions on medical supplies. Their caregivers, who were relatives from Malaysia, arrived just before border closures. Nonetheless, transplant surgery proceeded successfully with immediate graft function after methylprednisolone and thymoglobulin induction. She was maintained on prednisolone, mycophenolic acid, and tacrolimus and was discharged on postoperative day 9. To avoid overcrowding, nonurgent outpatient visits are generally deferred or conducted by phone. Patients are advised to perform blood sampling at nonpeak hours. The recipient is isolated in a clinic room after blood sampling before early review by her physician. Changes in her management are communicated by phone after her test results return if indicated. Both donor and recipient remain well 4 weeks posttransplant. As her condition stabilizes, some reviews will be performed via video conferencing. The considerations for transplantation during this pandemic are complex. Most transplantation bodies have suggested deferring nonurgent transplants and many healthcare systems are overloaded. However, with the pandemic expected to be protracted, transplants for patients with life‐threatening indications, such as malignancies, lung or heart transplants, and renal patients with risk of complete access failure cannot be deferred indefinitely. The risks of remaining on dialysis for a prolonged duration also need to be considered. We mitigated the risk of peritransplant COVID‐19 through diagnostic tests and stringent infection control measures. With increasing local community transmission, the risk of posttransplant COVID‐19 cannot be eliminated. Acquiring COVID‐19 during a state of profound immunosuppression may be devastating as emerging evidence suggests that immunocompromised patients are more likely to suffer severe complications. Moreover, there is no established treatment nor prophylaxis. Reducing immunosuppression for the management of COVID‐19 will entail significant risk of rejection. Unexpected disruptions to medical resources may also affect transplant care. Performing transplantation during a viral pandemic will continue to be challenging. Precautions to mitigate COVID‐19 transmission must be undertaken, and adequate healthcare resources must be secured before proceeding. Patient engagement is important, and we provide a possible framework for discussion (Table 1).
TABLE 1

Considerations for performing renal transplants during the coronavirus disease 2019 (COVID‐19) viral pandemic

UncertaintiesProceeding with transplantDeferring transplant

Evolving novel pathogen pandemic

Severity, extent, trajectory, and duration of the pandemic is unknown

Risk of healthcare‐associated, community‐acquired or donor‐derived infection

Potential adverse psychosocial effects due to heightened infection control measures for recipients (eg, social distancing, prolonged isolation)

Risk of healthcare‐associated (eg, dialysis center) or community‐acquired infection

Adverse medical and psychosocial effects from prolonged dialysis (eg, recurrent dialysis access‐related complications)

Loss of access to transplantation may be prolonged, with risk of exclusion from transplantation due to disease progression or death

Poorer posttransplant outcomes with prolonged duration on dialysis

Impact of COVID‐19 in different population groups (eg, transplant vs dialysis patients)

COVID‐19 may be more severe and potentially fulminant in transplant recipients, especially those with a higher net state of immunosuppression

Dialysis patients with medical comorbidities are likely also significantly vulnerable to severe COVID‐19

Treatment and prophylaxis options not established

Therapeutics for trial purposes or compassionate use may exclude transplant patients

Risk of drug‐drug interaction, especially with immunosuppressants

Reduction of immunosuppression to manage infection may put the graft at risk

Therapeutics for trial purposes or compassionate use may exclude dialysis patients

Impact on healthcare resources

Access to resources needed for transplantation may be disrupted

Transplant processes may compete for critical healthcare resources (eg, staff, medical supplies, and facilities) essential for pandemic response

Access to existing dialysis facilities may be affected

Risks to donor/caregivers

Risk of acquiring nosocomial COVID‐19 in healthy individuals

Caregivers may be as likely to acquire the infection in the community if widespread transmission occurs

Considerations for performing renal transplants during the coronavirus disease 2019 (COVID‐19) viral pandemic Evolving novel pathogen pandemic Severity, extent, trajectory, and duration of the pandemic is unknown Risk of healthcare‐associated, community‐acquired or donor‐derived infection Potential adverse psychosocial effects due to heightened infection control measures for recipients (eg, social distancing, prolonged isolation) Risk of healthcare‐associated (eg, dialysis center) or community‐acquired infection Adverse medical and psychosocial effects from prolonged dialysis (eg, recurrent dialysis access‐related complications) Loss of access to transplantation may be prolonged, with risk of exclusion from transplantation due to disease progression or death Poorer posttransplant outcomes with prolonged duration on dialysis COVID‐19 may be more severe and potentially fulminant in transplant recipients, especially those with a higher net state of immunosuppression Dialysis patients with medical comorbidities are likely also significantly vulnerable to severe COVID‐19 Therapeutics for trial purposes or compassionate use may exclude transplant patients Risk of drug‐drug interaction, especially with immunosuppressants Reduction of immunosuppression to manage infection may put the graft at risk Therapeutics for trial purposes or compassionate use may exclude dialysis patients Access to resources needed for transplantation may be disrupted Transplant processes may compete for critical healthcare resources (eg, staff, medical supplies, and facilities) essential for pandemic response Access to existing dialysis facilities may be affected Risk of acquiring nosocomial COVID‐19 in healthy individuals Caregivers may be as likely to acquire the infection in the community if widespread transmission occurs

DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
  3 in total

1.  Déjà Vu or Jamais Vu? How the Severe Acute Respiratory Syndrome Experience Influenced a Singapore Radiology Department's Response to the Coronavirus Disease (COVID-19) Epidemic.

Authors:  Lionel Tim-Ee Cheng; Lai Peng Chan; Ban Hock Tan; Robert Chun Chen; Kiang Hiong Tay; Moi Lin Ling; Bien Soo Tan
Journal:  AJR Am J Roentgenol       Date:  2020-03-04       Impact factor: 3.959

Review 2.  Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore.

Authors:  Jolin Wong; Qing Yuan Goh; Zihui Tan; Sui An Lie; Yoong Chuan Tay; Shin Yi Ng; Chai Rick Soh
Journal:  Can J Anaesth       Date:  2020-03-11       Impact factor: 6.713

3.  Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.

Authors:  Lan Zhu; Xizhen Xu; Ke Ma; Junling Yang; Hanxiong Guan; Song Chen; Zhishui Chen; Gang Chen
Journal:  Am J Transplant       Date:  2020-03-31       Impact factor: 8.086

  3 in total
  6 in total

Review 1.  Transplantation in Asia during the coronavirus disease-19 (COVID-19) pandemic: briefs from member countries of the Asian Society of Transplantation.

Authors:  Terence Kee; Jong Cheol Jeong; Jongwon Ha; Harun Ur Rashid; Nura Afza Salma Begum; Maggie K M Ma; Vivek Kute; Kenji Yuzawa; Rosnawati Yahya; Ghazali Ahmad; Lkhaakhuu Od-Erdene; Dibya Singh Shah; Romina A Danguilan; Curie Ahn; Devinder Singh Rana
Journal:  Korean J Transplant       Date:  2020-06-30

Review 2.  Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies.

Authors:  Paul A Trubin; Marwan M Azar; Maricar Malinis
Journal:  Curr Transplant Rep       Date:  2020-10-25

Review 3.  One Year on: An Overview of Singapore's Response to COVID-19-What We Did, How We Fared, How We Can Move Forward.

Authors:  S Vivek Anand; Yao Kang Shuy; Poay Sian Sabrina Lee; Eng Sing Lee
Journal:  Int J Environ Res Public Health       Date:  2021-08-30       Impact factor: 4.614

4.  Impact of the COVID-19 pandemic on transplantation by income level and cumulative COVID-19 incidence: a multinational survey study.

Authors:  Shaifali Sandal; Allan Massie; Brian Boyarsky; Teresa Po-Yu Chiang; Kednapa Thavorn; Dorry L Segev; Marcelo Cantarovich
Journal:  BMJ Open       Date:  2022-01-12       Impact factor: 2.692

Review 5.  Insights and pearls of healthcare systems management of COVID-19 in Asia and its relevance to Asian transplant services.

Authors:  Terence Kee
Journal:  Korean J Transplant       Date:  2021-09-30

Review 6.  Transplantation in the era of the Covid-19 pandemic: How should transplant patients and programs be handled?

Authors:  Mohamed M NasrAllah; Noha A Osman; Mahmoud Elalfy; Paolo Malvezzi; Lionel Rostaing
Journal:  Rev Med Virol       Date:  2020-09-20       Impact factor: 11.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.